Treatment with the NK1 antagonist emend reduces blood brain barrier dysfunction and edema formation in an experimental model of brain tumors

PLoS ONE

Volumn 9, Issue 5, 2014, Pages

  Harford Wright, Elizabeth ^a   Lewis, Kate M ^a   Ghabriel, Mounir N ^a   Vink, Robert ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; APREPITANT; DEXAMETHASONE; SUBSTANCE P; MORPHOLINE DERIVATIVE; NEUROKININ 1 RECEPTOR; NEUROKININ 1 RECEPTOR ANTAGONIST;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN EDEMA; BRAIN TUMOR; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; MEMBRANE PERMEABILITY; MOUSE; NONHUMAN; PATHOGENESIS; PROTEIN EXPRESSION; WATER CONTENT; ANIMAL; COMPLICATION; DISEASE MODEL; DRUG EFFECTS; METABOLISM; PERMEABILITY;

ANIMALS; BLOOD-BRAIN BARRIER; BRAIN EDEMA; BRAIN NEOPLASMS; DISEASE MODELS, ANIMAL; HUMANS; MALE; MICE; MORPHOLINES; NEUROKININ-1 RECEPTOR ANTAGONISTS; PERMEABILITY; RECEPTORS, NEUROKININ-1; SUBSTANCE P;

EID: 84901285594     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0097002     Document Type: Article

References (54)

1. AIHW (2010) Cancer - Australian cancer statistics update, May 2010. Australian Institute of Health and Welfare.
2. Lu-Emerson C, Eichler AF (2012) Brain metastases. Continuum (Minneap Minn) 18: 295-311.
3. Barnholtz-Sloan JS, Sloan AE, Davis FG, Vigneau FD, Lai P, et al. (2004) Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol 22: 2865-2872.
4. Ito U, Reulen HJ, Tomita H, Ikeda J, Saito J, et al. (1990) A computed tomography study on formation, propagation, and resolution of edema fluid in metastatic brain tumors. Adv Neurol 52: 459-468.
5. Groger U, Huber P, Reulen HJ (1994) Formation and resolution of human peritumoral brain edema. Acta Neurochir Suppl (Wien) 60: 373-374.
6. Papadopoulos MC, Saadoun S, Binder DK, Manley GT, Krishna S, et al. (2004) Molecular mechanisms of brain tumor edema. Neuroscience 129: 1011-1020.
7. Johansson BB (1990) The Physiology of the blood brain barrier. In: Porter JCJD, editor. Circulating regulatroy factors and neuroendocrine function. New York: Plenum Press. pp. 25-39.
8. Shibata S (1989) Ultrastructure of capillary walls in human brain tumors. Acta Neuropathol 78: 561-571.
9. Harford-Wright E, Thornton E, Vink R (2010) Angiotensin-converting enzyme (ACE) inhibitors exacerbate histological damage and motor deficits after experimental traumatic brain injury. Neurosci Lett 481: 26-29.
10. Donkin JJ, Nimmo AJ, Cernak I, Blumbergs PC, Vink R (2009) Substance P is associated with the development of brain edema and functional deficits after traumatic brain injury. J Cereb Blood Flow Metab 29: 1388-1398.
11. Vink R, Young A, Bennett CJ, Hu X, Connor CO, et al. (2003) Neuropeptide release influences brain edema formation after diffuse traumatic brain injury. Acta Neurochir Suppl 86: 257-260.
12. Turner RJ, Helps SC, Thornton E, Vink R (2011) A substance P antagonist improves outcome when administered 4 h after onset of ischaemic stroke. Brain Res 1393: 84-90.
13. Rosso M, Robles-Frias MJ, Covenas R, Salinas-Martin MV, Munoz M (2008) The NK-1 receptor is expressed in human primary gastric and colon adenocarcinomas and is involved in the antitumor action of L-733,060 and the mitogenic action of substance P on human gastrointestinal cancer cell lines. Tumour Biol 29: 245-254.
14. Munoz M, Rosso M, Robles-Frias MJ, Salinas-Martin MV, Rosso R, et al. (2010) The NK-1 receptor is expressed in human melanoma and is involved in the antitumor action of the NK-1 receptor antagonist aprepitant on melanoma cell lines. Lab Invest 90: 1259-1269.
15. Esteban F, Gonzalez-Moles MA, Castro D, Martin-Jaen Mdel M, Redondo M, et al. (2009) Expression of substance P and neurokinin-1-receptor in laryngeal cancer: linking chronic inflammation to cancer promotion and progression. Histopathology 54: 258-260.
16. Lewis KM, Harford-Wright E, Vink R, Ghabriel MN (2013) NK1 receptor antagonists and dexamethasone as anticancer agents in vitro and in a model of brain tumours secondary to breast cancer. Anticancer Drugs 24: 344-354.
17. Watanabe Y, Asai H, Ishii T, Kiuchi S, Okamoto M, et al. (2008) Pharmacological characterization of T-2328, 2-fluoro-4′-methoxy-3′- [[[(2S,3S)-2-phenyl-3-piperidinyl]amino]methyl]-[1,1′-biph enyl]-4-carbonitrile dihydrochloride, as a brain-penetrating antagonist of tachykinin NK1 receptor. J Pharmacol Sci 106: 121-127.
18. Lewis KM, Harford-Wright E, Vink R, Ghabriel MN (2012) Targeting classical but not neurogenic inflammation reduces peritumoral oedema in secondary brain tumours. J Neuroimmunol.
19. Helps SC, Thornton E, Kleinig TJ, Manavis J, Vink R (2011) Automatic nonsubjective estimation of antigen content visualized by immunohistochemistry using color deconvolution. Appl Immunohistochem Mol Morphol 20: 82-90.
20. Ruifrok AC, Johnston DA (2001) Quantification of histochemical staining by color deconvolution. Anal Quant Cytol Histol 23: 291-299.
21. Kleinig TJ (2010) The Role of Substance P in Experimental Intracerebral Hemorrhage. Adelaide: University of Adelaide.
22. Turner RJ, Blumbergs PC, Sims NR, Helps SC, Rodgers KM, et al. (2006) Increased substance P immunoreactivity and edema formation following reversible ischemic stroke. Acta Neurochir Suppl 96: 263-266.
23. Jamshidi J, Yoshimine T, Ushio Y, Hayakawa T (1992) Effects of glucocorticoid and chemotherapy on the peritumoral edema and astrocytic reaction in experimental brain tumor. J Neurooncol 12: 197-204.
24. Engelhorn T, Savaskan NE, Schwarz MA, Kreutzer J, Meyer EP, et al. (2009) Cellular characterization of the peritumoral edema zone in malignant brain tumors. Cancer Sci 100: 1856-1862.
25. Siu T, Huang S (2010) Cerebral Metastases from Malignant Melanoma: Current Treatment Strategies Advances in Novel Therapeutics and Future Directions. Cancers 2: 364-375.
26. Criscuolo GR (1993) The genesis of peritumoral vasogenic brain edema and tumor cysts: a hypothetical role for tumor-derived vascular permeability factor. Yale J Biol Med 66: 277-314.
27. Bafaloukos D, Gogas H (2004) The treatment of brain metastases in melanoma patients. Cancer Treat Rev 30: 515-520.
28. Patchell RA (2003) The management of brain metastases. Cancer Treat Rev 29: 533-540.
29. Sharkey FE, Fogh J (1984) Considerations in the use of nude mice for cancer research. Cancer Metastasis Rev 3: 341-360.
30. Gabrielian L, Helps SC, Thornton E, Turner RJ, Leonard AV, et al. (2013) Substance P antagonists as a novel intervention for brain edema and raised intracranial pressure. Acta Neurochir Suppl 118: 201-204.
31. Lewis KM, Harford-Wright E, Vink R, Nimmo AJ, Ghabriel MN (2012) Walker 256 tumour cells increase substance P immunoreactivity locally and modify the properties of the blood-brain barrier during extravasation and brain invasion. Clin Exp Metastasis.
32. Leonard AV, Thornton E, Vink R (2013) Substance P as a mediator of neurogenic inflammation after balloon compression induced spinal cord injury. J Neurotrauma 30: 1812-1823.
33. Rosso M, Munoz M, Berger M (2012) The role of neurokinin-1 receptor in the microenvironment of inflammation and cancer. ScientificWorldJournal 2012: 381434.
34. Richardson JD, Vasko MR (2002) Cellular mechanisms of neurogenic inflammation. J Pharmacol Exp Ther 302: 839-845.
35. Schaffer M, Beiter T, Becker HD, Hunt TK (1998) Neuropeptides: mediators of inflammation and tissue repair? Arch Surg 133: 1107-1116.
36. Quinlan KL, Naik SM, Cannon G, Armstrong CA, Bunnett NW, et al. (1999) Substance P activates coincident NF-AT- and NF-kappa B-dependent adhesion molecule gene expression in microvascular endothelial cells through intracellular calcium mobilization. J Immunol 163: 5656-5665.
37. Cioni C, Renzi D, Calabro A, Annunziata P (1998) Enhanced secretion of substance P by cytokine-stimulated rat brain endothelium cultures. J Neuroimmunol 84: 76-85.
38. Hafstrom I, Gyllenhammar H, Palmblad J, Ringertz B (1989) Substance P activates and modulates neutrophil oxidative metabolism and aggregation. J Rheumatol 16: 1033-1037.
39. Lin RC (1995) Reactive astrocytes express substance-P immunoreactivity in the adult forebrain after injury. Neuroreport 7: 310-312.
40. Harford-Wright E, Lewis KM, Vink R (2013) The Potential for Substance P Antagonists as Anti-Cancer Agents in Brain Tumours. Recent Pat CNS Drug Discov.
41. Akazawa T, Kwatra SG, Goldsmith LE, Richardson MD, Cox EA, et al. (2009) A constitutively active form of neurokinin 1 receptor and neurokinin 1 receptor-mediated apoptosis in glioblastomas. J Neurochem 109: 1079-1086.
42. Munoz M, Rosso M, Perez A, Covenas R, Rosso R, et al. (2005) Antitumoral action of the neurokinin-1-receptor antagonist L-733,060 and mitogenic action of substance P on human retinoblastoma cell lines. Invest Ophthalmol Vis Sci 46: 2567-2570.
43. Palma C (2006) Tachykinins and their receptors in human malignancies. Curr Drug Targets 7: 1043-1052.
44. Harrison S, Geppetti P (2001) Substance p. Int J Biochem Cell Biol 33: 555-576.
45. Hariri RJ (1994) Cerebral edema. Neurosurg Clin N Am 5: 687-706.
46. Rodriguez PL, Jiang S, Fu Y, Avraham S, Avraham HK (2013) The pro-inflammatory peptide Substance P promotes blood-brain barrier breaching by breast cancer cells through changes in microvascular endothelial cell tight junctions. Int J Cancer.
47. Borson DB, Gruenert DC (1991) Glucocorticoids induce neutral endopeptidase in transformed human tracheal epithelial cells. Am J Physiol 260: L83-89.
48. Mendelsohn FA, Lloyd CJ, Kachel C, Funder JW (1982) Induction by glucocorticoids of angiotensin converting enzyme production from bovine endothelial cells in culture and rat lung in vivo. J Clin Invest 70: 684-692.
49. Skidgel RA, Erdos EG (1987) Cleavage of peptide bonds by angiotensin I converting enzyme. Agents Actions Suppl 22: 289-296.
50. Dietrich J, Rao K, Pastorino S, Kesari S (2011) Corticosteroids in brain cancer patients: benefits and pitfalls. Expert Rev Clin Pharmacol 4: 233-242.
51. Hockey B, Leslie K, Williams D (2009) Dexamethasone for intracranial neurosurgery and anaesthesia. J Clin Neurosci 16: 1389-1393.
52. Zhang RD, Price JE, Fujimaki T, Bucana CD, Fidler IJ (1992) Differential permeability of the blood-brain barrier in experimental brain metastases produced by human neoplasms implanted into nude mice. Am J Pathol 141: 1115-1124.
53. Hasegawa H, Ushio Y, Hayakawa T, Yamada K, Mogami H (1983) Changes of the blood-brain barrier in experimental metastatic brain tumors. J Neurosurg 59: 304-310.
54. Harford-Wright E, Lewis KM, Vink R, Ghabriel MN (2014) Evaluating the role of substance P in brain tumours. Neuroscience: 261: 85-94.